Immunogenicity and safety of an intramuscular A/H5N1 inactivated, split virion pandemic influenza vaccine in adults
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi; sanofi pasteur
- 24 Sep 2008 Primary outcome amended as reported by ClinicalTrials.gov.
- 24 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2008 Actual end date added as 1 Sep 2008 as reported by ClinicalTrials.gov.